Skip to main content
. 2017 Nov 29;12(11):e0188712. doi: 10.1371/journal.pone.0188712

Table 2. Gastrointestinal AEs observed in ≥2% of patients.

Gastrointestinal AEs, n (%) Ferric citrate (n = 190) Placebo (n = 188)
Any AE (≥2% of patients) 94 (49.5) 52 (27.7)
Feces discolored 41 (21.6) 0 (0.0)
Diarrhea 39 (20.5) 23 (12.2)
Constipation 35 (18.4) 19 (10.1)
Nausea 18 (9.5) 8 (4.3)
Abdominal pain 9 (4.7) 3 (1.6)
Vomiting 8 (4.2) 8 (4.3)
Flatulence 6 (3.2) 3 (1.6)
Abdominal discomfort 4 (2.1) 1 (0.5)
Dyspepsia 4 (2.1) 1 (0.5)

AE, adverse event.